Biopharma | February 24, 2026
ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
These results were consistent across all clinically relevant patient subgroups regardless of key patient characteristics like age or sex, the cause of stroke or the severity of the stroke
Hologic has been at the forefront of cervical cancer screening for decades
TruVerus is the only FDA cleared, multi-modal platform capable of delivering comprehensive routine testing from a single lithium heparin sample
Treatment typically requires frequent injections directly into the eye—an ongoing burden for patients and health systems alike
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
It's an acquisition that aims at forming one of the US's largest oncology trial networks
The partnership targets breakthroughs in Alzheimer’s disease, diabetes, cancer, and cell and gene therapy
The platform integrates with CT imaging and uses deep learning models to generate a 3D digital twin of lung anatomy
Despite steep funding setbacks, the global HIV response has gained momentum in 2025 with the introduction of twice-yearly injectable LEN
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
